Gavin Oudit led a team of UAlberta researchers that created a synthetic form of the peptide apelin. The breakthrough could lead to a new class of drugs for heart disease, high blood pressure and diabetes.
UAlberta researchers create drug that replaces key peptide linked with heart failure, diabetes and high blood pressure. Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes. Researchers at the U of A found that a deficiency in the peptide apelin is associated with heart failure, pulmonary hypertension and diabetes. They also developed a synthetic version that targets pathways in the heart and promotes blood vessel growth. Lead author Gavin Oudit, an associate professor in the Faculty of Medicine & Dentistry , said the synthetic form of apelin is far more stable and potent than the naturally occurring peptide, making drug therapies possible. "It's a new group of drugs that we hope can be used for a wide variety of disorders, all of which have a huge economic burden on the health-care system," said Oudit, a cardiologist and clinician-scientist at the Mazankowski Alberta Heart Institute. Oudit's research group studied apelin deficiency in the hearts of mice and humans through the Human Explanted Heart Program, or HELP.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
